Therapeutic Nuclear Medicines Market

Therapeutic Nuclear Medicines Market: Increasing Prescription of Radium-223 in Prostate Cancer Treatment to Propel Growth: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028

  • 2019-01-14
  • REP-GB-2930
  • 237 pages
  • PDF PPT EXCEL
Therapeutic Nuclear Medicines Market

An Incisive, In-depth Analysis on the Therapeutic Nuclear Medicines Market

This study offers a comprehensive, 360 degree analysis on the Therapeutic Nuclear Medicines market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Therapeutic Nuclear Medicines market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.

Tier 1 players contribute to more than 80% revenue share

The therapeutic nuclear medicines market is a highly consolidated market with top three leading players contributing 87.4% of the market share. The tier 1 players of the global therapeutic nuclear medicines market are Novartis AG, Bayer AG and GE Healthcare. Bayer AG alone accounts for a 78.9% market share of the therapeutic nuclear medicines market due to the high penetration of its brand Xofigo for the treatment of prostate cancer in the U.S. and Europe. Novartis AG accounts for the second largest share of the global market owing to its acquisition of Advanced Accelerator Applications in 2017. Tier 2 players, such as Curium Pharmaceuticals, Jubilant DraxImage, Spectrum Pharmaceuticals and Progenics Pharmaceuticals, Inc., collectively accounted for 9% of the global therapeutic nuclear medicines market in 2017.

Growing acceptance of radiopharmaceuticals for therapeutic purposes

Radiopharmaceuticals are being used for diagnosis as well as therapeutic purposes. However, radiopharmaceuticals are currently used for diagnostic purpose rather than therapeutic purposes. Currently, only 12-13% revenue of the global radiopharmaceutical market comes from therapeutic nuclear medicines, however, by 2030, therapeutic nuclear medicines are expected to gain around 60-65% revenue of the global radiopharmaceutical market due to the positive results of Xofigo for the treatment of prostate cancer and the launch of Iodine-131 for the treatment of hypothyroidism and thyroid cancer in developed countries. Moreover, the leading radiopharmaceutical manufacturers are collaborating with hospitals and cancer research institutes for the sale of their products, which has increased the acceptance of therapeutic nuclear medicines.

Launch of more efficient therapeutic nuclear medicines for prostate cancer treatment

In the past few years, more efficient therapeutic nuclear medicines have been launched, which have shown positive results for the treatment of various types of cancer. For instance, the launch of Xofigo (Radium-223) by Bayer for the treatment of prostate cancer and the launch of Lutathera (Lutetium-177) for the treatment of neuroblastoma and synovitis has created growth opportunities for the therapeutic nuclear medicines market over the forecast period. In addition, the launch of these products has boosted the demand for therapeutic nuclear medicines among patients and physicians as well as opened the door for the other pharmaceutical manufacturers to launch more efficient therapeutic nuclear medicines.

Growing prevalence of prostate cancer

The prevalence of prostate cancer is rising throughout the globe, especially in developed countries such as the U.S. and UK, which is fuelling the growth of the therapeutic nuclear medicines market. According to the U.K. cancer research organization, prostate cancer is the most common type of cancer in the U.K. Around 47,151 men were diagnosed with the prostate cancer in 2015. Similarly, according to American Cancer Society, prostate cancer is the most common cause of death in the U.S. Around 1 in 9 men are expected to be diagnosed with prostate cancer during their lifetime. Therefore, increase in the incidence of prostate cancer is expected to drive the therapeutic nuclear medicines market over the forecast period

Stringent regulatory guidelines by FDA

The production, storage and usage of radioisotopes requires proper precautions because radioisotopes generate radiation that can affect the mass population as well as the environment. Approvals from the Food and Drug Administration and Medicines and Healthcare Products Regulatory Agency is mandatory for any usage, storage, or production of radioisotopes. According to the Nuclear Regulatory Commission, approximately 6,000 licenses are maintained for the usage of radioactive materials, the violation of which leads to enforcement actions that include loss of license. This stringent regulatory guideline by FDA for the approval and production of radiopharmaceuticals is likely to hamper the revenue growth of the therapeutic nuclear medicines market.

Competitive Landscape

The competition section of the therapeutic nuclear medicines market report features the profiles of the key players of the therapeutic nuclear medicines market based on their product offerings, market shares, marketing approach and differential strategies. Some of the key players profiled in the therapeutic nuclear medicines market report include Bayer AG, Novartis AG, GE Healthcare, Curium Pharmaceuticals, Jubilant DraxImage, Spectrum Pharmaceuticals, Progenics Pharmaceuticals, Inc., ANSTO, Lantheus Medical Imaging, Inc., Eckert & Ziegler and International Isotopes Inc.

Definition

Therapeutic nuclear medicines is a pharmaceutical formulation that consists of radioactive substances (radioisotopes). Therapeutic nuclear medicines are intend for the treatment of cancer, metastatic bone tumor and other diseases. The radioactive material of therapeutic nuclear medicines is capable of killing the cancerous tissue, reducing the size of a tumour and reducing pain.

About the Report

FMI conducted a research study on the therapeutic nuclear medicines market for the forecast period 2018 to 2028. The therapeutic nuclear medicines market report offers a comprehensive evaluation of the business opportunities prevailing in the therapeutic nuclear medicines market, along with insights on the pipeline assessment, key regulations and reimbursement scenario. The report on the therapeutic nuclear medicines market also elaborates on the macro-economic factors influencing the dynamics of the therapeutic nuclear medicines market and its futuristic potential.

Segmentation

The report offers a comprehensive taxonomy of the therapeutic nuclear medicines market based on the radionuclide type, indication, distribution channel and region. Some of the therapeutic nuclear medicines that are used for the treatment of cancer are Radium-223, Iodine-131, Leutitium-177, Yttrium-90, Samarium-153, Strontium-89, Rhenium-188+ Rhenium-186, Erbium-169 and Phosphorus-32. All these radionuclide types are taken into consideration while estimating and forecasting the therapeutic nuclear medicines market value. Indications, such as prostate cancer, painful bone metastases, thyroid cancer, neuroblastoma, synovitis, non-Hodgkins lymphoma, hepatic metastases, brain tumour and others, are included in the indication segment of the report. The global therapeutic nuclear medicines market report also includes the distribution channel segment that covers hospitals, ambulatory surgical centres and cancer research institutes. The therapeutic nuclear medicines market has been analysed across the regions of North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding China and Japan, China, Japan and MEA.

Additional Questions Answered

Some of the additional questions addressed in this report on the therapeutic nuclear medicines market are:

  • What is the revenue potential of Radium-223 across the regions of North America and Europe?

  • Who are the key competitors of the therapeutic nuclear medicines market and what are their product portfolios and growth strategies?

  • What are the major factors influencing the growth of the therapeutic nuclear medicines market?

  • Which trends are being followed by the leading manufacturers to retain their market share?

  • What is the prevalence and treatment-seeking rate for therapeutic nuclear medicines in the top countries?

Research Methodology

Top down analysis is used to estimate the market value of the global therapeutic nuclear medicines market. An exhaustive list of manufactures and their brands is prepared based on secondary research. The revenue generated by each brand of therapeutic nuclear medicines is tap down. The addition of revenue from all the brands of therapeutic nuclear medicines reflects the market value. The percent share of therapeutic nuclear medicines in the global radiopharmaceutical market is also analysed to calculate the market value. This information is further validated with rigorous primary research (including interviews, surveys, in-person interactions and the viewpoints of seasoned analysts) and secondary research (including verified paid sources, authentic trade journals and resourceful databases). The research study on the therapeutic nuclear medicines market also includes the top trends and macro- as well as micro-economic factors shaping the therapeutic nuclear medicines market. With this approach, the report on the therapeutic nuclear medicines market estimates the industry attractiveness of every major segment in the therapeutic nuclear medicines market over the forecast period.

A recent market study published by FMI – “Therapeutic Nuclear Medicines Market: Global Industry Analysis 2013-2017 & Opportunity Assessment 2018-2028” consists of a comprehensive assessment of the most important market dynamics. On conducting a thorough research of the historic as well as current growth parameters of the therapeutic nuclear medicines market, the growth prospects are obtained with maximum precision. The therapeutic nuclear medicines market report features the unique and salient factors that are likely to significantly impact the development of the therapeutic nuclear medicines market during the forecast period. It can help market players to modify their manufacturing and marketing strategies to envisage maximum growth in the therapeutic nuclear medicines market in the upcoming years. The report provides detailed information about the current and future growth prospects of the therapeutic nuclear medicines market in the most comprehensive manner for the better understanding of readers.

Chapter 1 – Executive Summary

The therapeutic nuclear medicines market report commences with an executive summary of the key findings and key statistics of the therapeutic nuclear medicines market. It also includes the market value (US$ million) estimates of the leading segments of the therapeutic nuclear medicines market.

Chapter 2 – Market Introduction

Readers can find detailed taxonomy and the definition of the therapeutic nuclear medicines market in this chapter, which helps understand the basic information about the therapeutic nuclear medicines. This section also highlights the inclusions and exclusions, which helps the reader understand the scope of the therapeutic nuclear medicines market report.

Chapter 3 – Global Economic Outlook

This section highlights the healthcare spending of the top countries in each region. This section also explains the global and regional healthcare market outlook. The regional healthcare market focuses is analysed in depth to assess the political, economic and business environment outlook of the respective region.

Chapter 4 – Market Opportunity Analysis

This chapter explains the key macro-economic factors that are expected to influence the growth of the therapeutic nuclear medicines market over the forecast period. Along with macroeconomic factors, this section also highlights the opportunity analysis for the therapeutic nuclear medicines market. It helps readers understand the market opportunity, based on which they can plan their strategies.

Chapter 5 – Market Dynamics

This chapter highlights the key dynamics of the therapeutic nuclear medicines market, which include the drivers, restraints and trends. The supply-side drivers as well as the demand-side drivers of the therapeutic nuclear medicines market are explained well in this chapter. This chapter is expected to enable readers to understand the factors that are propelling the therapeutic nuclear medicines market, as well as those that are likely to hamper the growth of the therapeutic nuclear medicines market. Moreover, readers will understand the key trends followed by the leading manufacturers in the therapeutic nuclear medicines market.

Chapter 6 – Key Inclusions

This chapter highlights the key inclusions of the therapeutic nuclear medicines market report, which include key regulations, reimbursement scenario and pipeline assessment. The analysis of the parent market helps readers understand the share of the global therapeutic nuclear medicines market in the overall radiopharmaceutical market. The key regulations section of this chapter highlights the FDA and EMA regulatory processes for the approval of drugs. The reimbursement scenario provides the CPT codes used for therapeutic nuclear medicines, as well as the detailed explanation about each CPT code. The pipeline assessment includes the list of clinical trials pertaining to therapeutic nuclear medicines around the globe.

Chapter 7 – North America Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter includes a detailed analysis of the growth of the North America therapeutic nuclear medicines market along with a country-wise assessment, which includes the U.S. and Canada. Readers can also find the key takeaways of this region, and market growth based on treatment type, disease type, end user and country of therapeutic nuclear medicines in the North America region.

Chapter 8 – Latin America Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter contains a snapshot of the Latin America therapeutic nuclear medicines market. It includes the growth prospects of the therapeutic nuclear medicines market in the leading LATAM countries such as Brazil, Mexico, Argentina and the rest of the Latin America region.

Chapter 9 – Western Europe Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

The important growth prospects of the therapeutic nuclear medicines market based on its radionuclide type, indication and distribution channel in several European countries, such as the U.K., Germany, France, Italy Spain and the rest of Western Europe, is included in this chapter.

Chapter 10 – Eastern Europe Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter highlights the growth of the therapeutic nuclear medicines market in Eastern Europe by focusing on Russia and Poland. This section also helps readers understand the key factors that are responsible for the growth of the therapeutic nuclear medicines market in Eastern Europe.

Chapter 11 – APECJ Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

Australia & New Zealand, India and ASEAN are the leading countries in the APECJ region that are the prime subjects of assessment to obtain the growth prospects of the APECJ therapeutic nuclear medicines market in this chapter. Readers can find detailed information about the growth parameters of the APEJ therapeutic nuclear medicines market during the period 2018-2028.

Chapter 12 – China Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

The key factors responsible for the robust growth of the China therapeutic nuclear medicines market is explained in this section. The market analysis by radionuclide type, indication and distribution channel of the therapeutic nuclear medicines market is explained in this section, which provides readers an in-depth analysis of the China therapeutic nuclear medicines market.

Chapter 13 – Japan Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

Readers can find important factors that can significantly impact the growth of the therapeutic nuclear medicines market in Japan during the forecast period based on the market segmentation.

Chapter 14 – MEA Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter provides information about the growth of the therapeutic nuclear medicines market in the major countries of the MEA region, such as GCC Countries and South Africa, during the period 2018-2028.

Chapter 15 – Forecast Factors – Relevance and Impact

This chapter highlights the key factors taken into consideration which forecasting the market value of the global therapeutic nuclear medicines market. The impact of this forecast factor in different regions is also mentioned in this chapter.

Chapter 16 – Market Structure Analysis

This section explains the tier structure of the global therapeutic nuclear medicines market, which helps readers understand the percent share of the market based on the tier 1, tier 2 and tier 3 players in the therapeutic nuclear medicines market. This section also explains the company share analysis for the therapeutic nuclear medicines market, which helps readers understand the market share held by the key players of the therapeutic nuclear medicines market.

Chapter 17 – Competition Landscape

In this chapter, readers can find a comprehensive list of all the leading manufacturers in the therapeutic nuclear medicines market, along with detailed information about each company, which includes the company overview, revenue shares, strategic overview, recent company developments and SWOT analysis.  Some of the players featured in the therapeutic nuclear medicines market report are Bayer AG, Novartis AG, GE Healthcare, Curium Pharmaceuticals, Jubilant DraxImage, Spectrum Pharmaceuticals, Progenics Pharmaceuticals, Inc., ANSTO, Lantheus Medical Imaging, Inc., Eckert & Ziegler and International Isotopes Inc.

Chapter 18 – Global Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028, By Region

This chapter explains how the therapeutic nuclear medicines market will grow across various geographic regions such as North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific Excluding Japan (APECJ), China, Japan and the Middle East & Africa (MEA).

Chapter 19 – Global Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028, By Radionuclide Type

Based on the treatment type, the therapeutic nuclear medicines market is segmented into Radium-223, Iodine-131, Leutitium-177, Yttrium-90, Samarium-153, Strontium-89, Rhenium-188+ Rhenium-186, Erbium-169, Phosphorus-32 and others. In this chapter, readers can find a detailed analysis of the therapeutic nuclear medicines market by different radionuclide types and their expected growth over the forecast period.

Chapter 20 – Global Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028, By Indication

Based on the indication, the therapeutic nuclear medicines market is segmented as prostate cancer, painful bone metastases, thyroid cancer, neuroblastoma, synovitis, non-Hodgkins lymphoma, hepatic metastases, brain tumour and others. This section helps readers understand the penetration of different indications in the therapeutic nuclear medicines market over the forecast period.

Chapter 21 – Global Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment 2018-2028, By Distribution Channel

Based on the distribution channel, the therapeutic nuclear medicines market is segmented into hospitals, ambulatory surgical centres and cancer research institutes. In this chapter, readers can understand the market attractive analysis based on the distribution channel.

Chapter 22 – Global Therapeutic Nuclear Medicines Market Analysis 2013-2017 & Opportunity Assessment, 2018-2028

This section explain the global market analysis and forecast for the therapeutic nuclear medicines market. It also highlights the incremental opportunity for the therapeutic nuclear medicines market along with the absolute dollar opportunity for every year between the forecast period of 2018-2028. 

Chapter 23 – Assumptions and Acronyms

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.

Chapter 24 – Research Methodology

This chapter helps readers understand the research methodology followed to obtain various conclusions and important qualitative information & quantitative information about the therapeutic nuclear medicines market.

Therapeutic Nuclear Medicines Market Reports - Table of Contents

Get in touch

Harish Tiwari

Harish Tiwari

Global Head - Business Development

Pranay Mhaisekar

Pranay Mhaisekar

Business Development

* indicates mandatory fields.

Our Clients


CASE STUDIES

See how our work makes an impact.

At FMI, we design strategies that are adaptive, impactful, and implementable.

Request Sample Ask An Analyst Request Special Price Request Methodology